Se hai scelto di non accettare i cookie di profilazione e tracciamento, puoi aderire all’abbonamento "Consentless" a un costo molto accessibile, oppure scegliere un altro abbonamento per accedere ad ANSA.it.

Ti invitiamo a leggere le Condizioni Generali di Servizio, la Cookie Policy e l'Informativa Privacy.

Puoi leggere tutti i titoli di ANSA.it
e 10 contenuti ogni 30 giorni
a €16,99/anno

  • Servizio equivalente a quello accessibile prestando il consenso ai cookie di profilazione pubblicitaria e tracciamento
  • Durata annuale (senza rinnovo automatico)
  • Un pop-up ti avvertirà che hai raggiunto i contenuti consentiti in 30 giorni (potrai continuare a vedere tutti i titoli del sito, ma per aprire altri contenuti dovrai attendere il successivo periodo di 30 giorni)
  • Pubblicità presente ma non profilata o gestibile mediante il pannello delle preferenze
  • Iscrizione alle Newsletter tematiche curate dalle redazioni ANSA.


Per accedere senza limiti a tutti i contenuti di ANSA.it

Scegli il piano di abbonamento più adatto alle tue esigenze.

Italians find one of engines behind pancreatic cancer

Italians find one of engines behind pancreatic cancer

Therapeutic target ID'd to hopefully slow advance of disease

01 novembre 2023, 18:10

Redazione ANSA

ANSACheck

Pancreatic cancer cells (credit: Min Yu/Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC,USC Norris Comprehensive Cancer Center, Pancreatic Desmoplasia, da Flickr) - RIPRODUZIONE RISERVATA

Pancreatic cancer cells (credit: Min Yu/Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC,USC Norris Comprehensive Cancer Center, Pancreatic Desmoplasia, da Flickr) - RIPRODUZIONE RISERVATA
Pancreatic cancer cells (credit: Min Yu/Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at USC,USC Norris Comprehensive Cancer Center, Pancreatic Desmoplasia, da Flickr) - RIPRODUZIONE RISERVATA

A team of Italian scientists have found one of the engines that drive cancer of the pancreas, one of the most aggressive tumours, in a discovery that has enabled them to identify a therapeutic target to hopefully slow the advance of the disease.

The research has been led by Milan's Istituto San Raffaele, with the Istituto Telethon of gene therapy and the Università Vita e Salute. Also working on the project were the universities of Turin and Verona, the French Institute For Health and Medical Research (INSERM), the Biopolis research centre in Singapore and the University of Shanghai.

Favouring the growth of this form of tumour which is still sadly very lethal, the ductal adenocarcinoma of the pancreas, is a special alliance between a particular type of immune cells, called IL-1beta+ macrophages, and some very aggressive tumour cells, known for being linked to inflammation. "It's a sort of self-feeding vicious circle," said research leader Renato Ostuni, head of the Innate Immune System Genomics Lab at the Istituto Sr-Tiget and associate professor at the Università Vita-Salute San Raffaele.
"The macrophages make the tumour cells more aggressive, and the tumour cells reprogramme the macrophages capable of favouring inflammation, and the progression of the disease".

The authors of the research said: "We have taken a good step forward in the understanding of the biological processes underlying the disease. However, we are at a stage of pre-clinical research, still distant from application in patients.

"The coming years will be essential to identify the potentialities and the most appropriate modalities to act on this new therapeutic target". The project was backed by Fondazione Airc , Italy's cancer research foundation, the European Research Council, and the Italian health ministry.

Riproduzione riservata © Copyright ANSA

Da non perdere

Condividi

O utilizza